Human Liver-Like 3D Construct for Hepatotoxicity Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing human liver models for drug toxicity testing contain mouse-derived cells, which complicates the assessment of human-specific toxicity due to the influence of mouse metabolic systems.
Innovation Solution
A human liver-like three-dimensional construct comprising a heterospheroid formed from an aggregate of human hepatocytes and human-derived cells other than hepatocytes, such as hepatic stellate cells, without the use of mouse-derived cells, allowing for accurate and simple assessment of human-specific toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human hepatocytes are co-cultured with mouse fibroblasts to improve liver function, then liver function is enhanced, but mouse metabolic effects contaminate human-specific toxicity assessment
Solution Approach 1:
The patent extracts and removes mouse fibroblasts from the co-culture system, replacing them with human-derived fibroblasts. This extraction of the harmful mouse cell component eliminates mouse metabolic effects while preserving the beneficial support function that fibroblasts provide to hepatocytes, thereby resolving the contradiction between enhancing liver function and eliminating mouse metabolic contamination.
Solution Approach 2:
The patent changes the species parameter of the fibroblast component from mouse to human. By modifying this biological parameter, the system maintains the functional benefits of fibroblast-coconut culture (improved liver function) while eliminating the harmful mouse-specific metabolic pathways, thus achieving human-specific toxicity assessment without mouse metabolic interference.
2Measurement precision
If mouse fibroblasts are used as negative control, then control group is established, but co-culture effects on mouse cells prevent accurate negative control
Solution Approach 1:
The patent applies homogeneity by using human-derived cells throughout the entire system - both in the test group (human hepatocytes with human fibroblasts) and the control group (human hepatocytes alone or with human fibroblasts). This eliminates species heterogeneity and ensures that any observed effects are truly due to the test substance rather than differences in cellular metabolic systems, thereby achieving both accurate toxicity assessment and reliable negative control.
3Object-affected harmful factors
If human hepatocytes are cultured alone, then human-specific toxicity can be assessed, but liver function is insufficient compared to co-culture systems
Solution Approach 1:
The patent introduces human fibroblasts as an intermediary cell type that mediates between the hepatocytes and the culture environment. These human fibroblasts provide necessary support functions (nutrient supply, waste removal, structural support) that enhance liver function, while being human-derived they do not interfere with human-specific toxicity assessment. The human fibroblasts act as a bridge that improves function without compromising assessment specificity.
Data Source
AI summary
Long awaited is a human liver-like three-dimensional construct that makes it possible to carry out evaluation of human-specific toxicity and the like accurately and in a simple manner. The present invention provides a human liver-like three-dimensional construct comprising a heterospheroid, in which human hepatic cells and other human-derived cells which are not human hepatic cells are aggregated. This human liver-like three-dimensional construct is characterized in that the other human-derived cells are at least one selected from human hepatic stellate cells and the like, and the other human-derived cell to the human hepatic cell count ratio is at least 0.01 but less than 1.